Currently health boards are developing local safe clinical pathways to support people on Liraglutide (Saxenda®). When the pathway has been agreed in NHS Fife we will be able to accept appropriate referrals for Liraglutide (Saxenda®).
National criteria for Liraglutide (Saxenda®) use throughout NHS Scotland has been confirmed. Apologies for the medical language, it is important to share the exact detail. The injectable medication, for the support of weight management, may be prescribed for those living with:
- Body Mass Index (BMI) greater than or equal to 35kg/m2
- Non-diabetic hyperglycaemia (prediabetes) at high risk of type 2 diabetes. For clarity, this is defined as having either:
- Fasting plasma glucose level of 5.5 to 6.9mmol/L or
- HbA1c of 42 to 47mmol/mol
- High risk of cardiovascular disease (CVD):
- Total cholesterol greater than 5mmol/L, or
- High-density lipoprotein (HDL) less than 1.0mmol/L for men and less than 1.3mmol/L for women, or
- Systolic blood pressure (SBP) greater than 140mmHg
- Patient needs to be treated within a NHS specialist weight management service.
Please note: this criteria is specific to Liraglutide’s use within weight management services; other criteria are associated with Liraglutide’s use for people with Type 2 Diabetes.
There will be no further updates on the Liraglutide (Saxenda®) weight management pathway until Liraglutide for weight management is added to the NHS Fife Formulary.
Local healthcare professionals will be able to advise when this is available. NHS Fife’s Weight Management web page will be updated to confirm when the pathway is live.
Find out more information about our programmes and referral forms